Stage IV Lung Cancer AJCC v8 Clinical Trial
Official title:
Embedded Palliative Care in the Management of Advanced Thoracic Malignancies
Verified date | October 2023 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies how well embedded palliative care works in managing symptoms in participants with stage III-IV thoracic malignancies that has come back and their caregivers. Embedded palliative care may improve distress and anxiety in participants and caregivers.
Status | Completed |
Enrollment | 68 |
Est. completion date | December 5, 2020 |
Est. primary completion date | December 5, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with advanced or metastatic cancer of the chest (lung, thymus, or pleura): stage III or IV, recurrent disease - Patients will receive therapy (chemotherapy, immunotherapy, targeted therapy or radiation therapy) at The Ohio State University - New patients (defined as patients who have received no therapy for metastatic disease or have started treatment for metastatic disease within the last 30 days) or established patients with advanced cancer receiving anti-cancer therapy, no limit on prior therapies - Patient and caregiver must be able to read and understand consent form - Patients must designate a willing caregiver to participate although caregiver consent is not required for patient participation Exclusion Criteria: - Patients who are already enrolled or have been previously enrolled in palliative care or hospice services as an outpatient. Inpatient palliative care consultation prior to enrollment is permitted - Patients who do not qualify for active anti-cancer therapy and opt to enroll in hospice services prior to study enrollment - Patients who are unable to read or understand consent form - Patients receiving primary systemic treatment outside of Ohio State. Outside radiation therapy is permitted |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acceptance from providers to assess utilization of palliative care services | Acceptance will be evaluated utilizing provider surveys (to capture provider opinions on palliative care utilization) as well as rate of enrollment. Preliminary data will be summarized and collected. Confidence intervals will also be calculated for feasibility rates. | Up to 12 months | |
Primary | Demand of palliative care services to be evaluated | Preliminary data will be summarized and collected. Confidence intervals will also be calculated for feasibility rates. | Up to 12 months | |
Primary | Capacity and productivity to be evaluated | Clinician capacity and productivity will be evaluated by looking at scheduling as well as billing productivity. Preliminary data will be summarized and collected. Confidence intervals will also be calculated for feasibility rates. | Up to 12 months | |
Primary | Resource assessment of staff and space | Resources required, including patient care rooms and nursing support will also be evaluated. Preliminary data will be summarized and collected. Confidence intervals will also be calculated for feasibility rates. | Up to 12 months | |
Primary | Symptom burden (patient outcome) supportive care screen | Will be assessed using Supportive care screen. | Up to 12 months | |
Primary | Symptom burden (patient outcome) Functional Assessment of Cancer Therapy-Lung | Will be assessed using Functional Assessment of Cancer Therapy-Lung | Up to 12 months | |
Primary | Symptom burden (patient outcome) using HADS | Will be assessed using Hospital Anxiety and Depression Scale (HADS) | Up to 12 months | |
Primary | Symptom burden using National Comprehensive Cancer Network distress thermometer (patient outcome) | Will be assessed using National Comprehensive Cancer Network distress thermometer | Up to 12 months | |
Primary | Anxiety assessment using Hospital Anxiety and Depression Scale (patient outcome) | Anxiety assessed using the Hospital Anxiety and Depression Scale | Up to 12 months | |
Primary | Depression assessment using Hospital Anxiety and Depression Scale (patient outcome) | Depression assessed using the Hospital Anxiety and Depression Scale | Up to 12 months | |
Primary | Functional status assessed using Functional Activities Scale (patient outcome) | Functional status assessment using Functional Activities Scale (FAS) | Up to 12 months | |
Primary | Health care service needs assessed using Supportive Care Needs Survey Partners and Caregivers (SCNS- P and C) (Caregiver outcome) | Caregiver needs assessment using Supportive Care Needs Survey - Patients & Caregivers (SCNC-P&C) | Up to 12 months | |
Primary | Psychological/emotional needs assessed using SCNS- P and C (Caregiver outcome) | Caregiver needs assessment using Supportive Care Needs Survey - Patients & Caregivers (SCNC-P&C) | Up to 12 months | |
Primary | Work/social needs assessed using SCNS- P and C (Caregiver outcome) | Caregiver needs assessment using Supportive Care Needs Survey - Patients & Caregivers (SCNC-P&C) | Up to 12 months | |
Primary | Information needs assessed using SCNS- P and C (Caregiver outcome) | Caregiver needs assessment using Supportive Care Needs Survey - Patients & Caregivers (SCNC-P&C) | Up to 12 months | |
Primary | Self-reported barriers and attitudes regarding palliative care assessed using Ohio State Palliative Care Provider Survey (Provider outcome) | Ohio State Palliative Care Provider survey used to assess perceived barriers to referral | Up to 12 months | |
Primary | Health care utilization outcomes | Will be captured using Integrated Health Information Systems electronic medical record data as well as patient reported events. | Up to 12 months | |
Secondary | Challenges for patients, caregivers, and the treating oncologist in an embedded palliative care model | evaluate the challenges for patients, caregivers and treating oncologist in embedded palliative care | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04267913 -
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT04151940 -
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
|
N/A | |
Terminated |
NCT03707925 -
Bronchoscopic Laser Ablation of Peripheral Lung Tumors
|
N/A | |
Active, not recruiting |
NCT04081688 -
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
|
Phase 1 | |
Recruiting |
NCT04929041 -
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04250545 -
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT04396535 -
Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04514497 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
|
Phase 1 | |
Withdrawn |
NCT05161533 -
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
|
Phase 2 | |
Recruiting |
NCT04919369 -
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT03662074 -
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04073745 -
Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer
|
Phase 1 | |
Withdrawn |
NCT04186988 -
[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy
|
Early Phase 1 | |
Active, not recruiting |
NCT03600701 -
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03637816 -
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
Recruiting |
NCT05234307 -
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06122064 -
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
|
N/A | |
Active, not recruiting |
NCT04533451 -
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03776253 -
Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer
|
N/A |